Patents by Inventor George Rudy

George Rudy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoreactive and immunotherapeutic molecules
    Patent number: 7455984
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with antibodies or T-cells in subjects having pre-clinical or clinical Insulin-Dependent Diabetes Mellitus (IDDM). These molecules are preferentially immunoreactive to T-cells in subjects having pre-clinical or clinical IDDM and are useful in the development of diagnostic, therapeutic and prophylactic agents for IDDM.
    Type: Grant
    Filed: January 7, 2002
    Date of Patent: November 25, 2008
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Leonard Harrison, Margo Honeyman, George Rudy, Andrew Lew
  • Immunoreactive peptides
    Patent number: 6818217
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with antibodies or T-cells in subjects having pre-clinical or clinical Insulin-Dependent Diabetes Mellitus (IDDM). These molecules are preferentially immunoreactive to T-cells in subjects having pre-clinical or clinical IDDM and are useful in the development of diagnostic, therapeutic and prophylactic agents for IDDM.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: November 16, 2004
    Assignee: AMRAD Corporation Limited
    Inventors: Leonard Harrison, Margo Honeyman, George Rudy, Andrew Lew
  • Immunoreactive and immunotherapeutic molecules
    Publication number: 20020142004
    Abstract: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with antibodies or T-cells in subjects having pre-clinical or clinical Insulin-Dependent Diabetes Mellitus (IDDM). These molecules are preferentially immunoreactive to T-cells in subjects having pre-clinical or clinical IDDM and are useful in the development of diagnostic, therapeutic and prophylactic agents for IDDM.
    Type: Application
    Filed: January 7, 2002
    Publication date: October 3, 2002
    Inventors: Leonard Harrison, Margo Honeyman, George Rudy, Andrew Lew